P134: Home based faecal calprotectin testing: a Canadian user performance evaluation study of IBDoc®ECCO '18 Vienna
2018
P135: Real-world use of faecal calprotectin testing in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P136: Serum IL-17 and IL-23 levels can distinguish between severe and non-severe inflammatory bowel diseaseECCO '18 Vienna
2018
P137: Clinical and pathological correlations between primary and secondary ileal strictures in Crohn’s diseaseECCO '18 Vienna
2018
P138: Isolated ileal blind loop inflammation after ileocolonic resection in Crohn’s disease: An often neglected diagnosis with an unfavourable prognosisECCO '18 Vienna
2018
P140: Physician attitudes about the use of immunosuppressive therapy for inflammatory bowel disease in the elderlyECCO '18 Vienna
2018
P141: Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective studyECCO '18 Vienna
2018
P142: Danese’s “Red flag Instrument” is ready for clinical practice: the RFi prospective validationECCO '18 Vienna
2018
P143: Risk of impaired nutritional status is associated with an unfavourable disease outcome in IBDECCO '18 Vienna
2018
P144: Comparison between faecal chitinase 3-like 1, matrix metalloprotease 9, and calprotectin to assess mucosal healing in Crohn’s disease: a multicentre prospective studyECCO '18 Vienna
2018
P147: Presence of granulomas in tissue samples from Crohn’s disease patients correlates with specific disease characteristicsECCO '18 Vienna
2018
P150: Low diagnostic accuracy of faecal calprotectin to predict mucosal inflammation in Crohn’s disease patients with active perianal fistulasECCO '18 Vienna
2018
P151: Characteristics of presentation and risk factors for early recurrence after strictureplasty for Crohnメs disease of the small bowel in the biological eraECCO '18 Vienna
2018
P152: Fertility and reproduction in a tertiary IBD centre: the Oxford experienceECCO '18 Vienna
2018